Devices

 News Release - March 13, 2006

Tutogen Medical, Inc. Contacted by Zimmer Holdings, Inc. to Discuss Potential Strategic Transactions

Range of Potential Transactions Include, But Not Limited to:

• Further Investment by Zimmer in Securities of TTG or,
• The Acquisition by Zimmer of Some or All of the Outstanding Common Stock of TTG

Zimmer Holdings, Inc. filed Schedule 13 D/A on Friday, March 10, 2006 expressing its intention to initiate discussions with Tutogen Medical, Inc.

Guy L. Mayer, president and CEO of Tutogen Medical, said, "We have made a great deal of progress in the past year in positioning the Company for improved performance. We believe this approach by Zimmer is indicative of that progress. We look forward to considering any and all strategic options that will help us to expand the reach of our products worldwide and that will appropriately enhance value for our loyal shareholders."

About Tutogen Medical, Inc.

Tutogen Medical, Inc. manufactures sterile biological implant products made from human (allograft) and animal (xenograft) tissue. Tutogen utilizes its Tutoplast Process® of tissue preservation and viral inactivation to manufacture and deliver sterile bio-implants used in spinal/trauma, urology, dental, ophthalmology, and general surgery procedures. The Company's Tutoplast® products are sold and distributed worldwide by Zimmer Spine and Zimmer Dental, subsidiaries of Zimmer Holdings, Inc. the Mentor Corporation, IOP, Inc. and through independent distributors and subsidiaries in the U.S. and other international markets. For more information, visit the Company's Web site at http://www.tutogen.com .

Forward-Looking Statement Disclaimer: Certain statements in this news release are forward-looking and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties, which may differ materially from those set forth in these statements. In addition, the economic, competitive, governmental, technological and other factors identified in the Company's filings with the Securities and Exchange Commission could affect such results.

Source: Tutogen Medical

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.